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Application of endograft to treat thoracic aortic
pathologies: A single center experience
Julio A. Rodriguez, MD, Dawn M. Olsen, PAC, Alena Shtutman, RT, Leonardo Aguiar Lucas, MD,
Grayson Wheatley, MD, Jeffrey Alpern, DO, Venkatesh Ramaiah, MD, and Edward B. Diethrich, MD,
Phoenix, Ariz
Purpose: To evaluate our experience of thoracic endoluminal graft (ELG) repair of various thoracic aortic pathologies
using a commercially available device approved by the Food and Drug Administration. Our patient population includes
patients eligible for open surgical repair and those with prohibitive surgical risk.
Methods: FromMarch 1998 toMarch 2006, endovascular stent repair of the thoracic aorta was performed on 406 patients
with 324 patients (median age 72; 200 male) receiving the Gore Excluder endograft. Patient demographics, procedural
characteristics, complications, including endoleak, spinal cord ischemia, and mortality, were retrospectively reviewed
during follow-up. All patients were followed with chest computer tomography at 6 months and yearly. Statistical analysis
was performed utilizing the SPSS Windows 11.0 program. Logistic regression (univariate) analysis used to identify risk
factors for paraplegia; analysis of variance (ANOVA) for endoleak distribution; and 2 used to analyze variables. Survival
analysis was done using SAS version 9.1 (SAS Institute, Cary, NC).
Results: Three hundred twenty-four patients were treated with Gore Excluder graft between March 1998 and March 2006.
Onehundredfifty-seven patients (48.5%) had atherosclerotic aneurysms, 82 (25.3%) haddissections typeB (DTB), 34 (10.5%)
had penetrating ulcers (PU), 26 (8.0%) with pseudoaneurysms (PSA), 11 (3.4%) had transections (MVAT), 9 (2.8%)
aorto-bronchial fistulas (AoBF), 4 (1.2%) embolization, and 1 (0.3%) aorto-esophageal fistula (AoEF). Preoperative aneurysm
sac size in TAA ranged from 5 to 12 centimeters, average size 6.3 cm. Sac shrinkage occurred in 65% (102 of 157) of patients.
Average postoperative sac size of 5.4 cm in amean follow-up of 20.4months. One hundred cases (31.5%) were nonelective; 49
(15.1%) were ruptures. Overall complication was 22.7%, 14.2% (46) in elective cases and 8.5% (28) in nonelective cases.
Paraplegia occurred in five (1.5%) patients and paresis in three (0.9%); two of the latter improved and one resolved completely
prior to discharge. Incidence of paraplegia was statistically significant (P value < .05) with retroperitoneal approach,
perioperative blood loss greater than 1000 cc, and aortic coverage greater than 40 cm. Early endoleaks included 18 (5.5%) type
I, four (1.2%) type II, and two (0.6%) type III. Thirty-daymortalitywas 5.5% (18 related deaths, including three intraoperative
deaths). A log rank test did not find statistical differences in actuarial survival with 30-day relatedmortality between TAA and
other pathologies (P  .29) or between DTB and other pathologies (P  .97). Late mortality was 9.6% with 31 unrelated
deaths. Follow-up ranged between 1 month and 70 months, average 17 months.
Conclusions: Endoluminal grafting is a feasible alternative to open surgical repair for thoracic aortic pathologies. After
more than 300 cases, 30-day morbidity and mortality compares favorably with open repair. Paraplegia remains low as a
complication and increases in incidence with retroperitoneal approach, increased perioperative blood loss, and increased
aortic coverage. (J Vasc Surg 2007;46:413-20.)Surgical treatment of the thoracic aorta can be challeng-
ing to the surgeon due to the potential perioperative morbid-
ities. With more complex thoracic aortic pathology, difficult
anatomy, and less than fit patients, these morbidities increase.
Surgical morbidity is significant and may include stroke,
myocardial infarction, pulmonary insufficiency, renal
insufficiency/failure and paralysis.1-5 Paraplegia for an iso-
lated descending thoracic aneurysm is as much as 4%.6
Endoluminal stent grafting (ELG) has been recently con-
sidered a possible alternative. Initial series documented com-
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Paraplegia, one of the most devastating complications,
seemed less prevalent. The US nonrandomized clinical con-
trolled trial with the Gore-Tag device (W. L. Gore, Flagstaff,
Ariz) comparing the ELG vs open repair led to the approval of
the endograft to be used in descending thoracic aneurysms.
This trial demonstrated advantages over the open cohort
when 30-day mortality and paraplegia were considered.19
More recent series reviewing early results indicate that this is a
feasible option for patients not only with atherosclerotic an-
eurysms butwith a variety of other thoracic aortic pathologies,
however, long-term benefits have yet to be proven.20-26 We
report a single center experience using the Gore Excluder/
Tag graft to treat various thoracic aorta pathologies; early and
late follow-up are included.
METHODS
Between March 1998 and March 2006, 406 patients
were treated with an endoluminal graft at the Arizona
Heart Hospital. Of these patients, 324 patients (median
413
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device to manage 157 (48.5%) aneurysms (TAA), 82
(25.3%) type B dissections (DTB), 34 (10.5%) penetrating
ulcers (PU), 26 (8%) pseudoaneurysms (PSA), 11 (3.4%)
aortic transections, 9 (2.8%) aortobronchial fistulas, 4
(1.2%) embolization, and 1 (0.3%) aorto-esophageal fis-
tula. Prior to Food and Drug Administration (FDA) ap-
proval, all patients were enrolled under the guidelines of the
FDA Investigational Devices Exemption (IDE) for the
Gore Excluder or Gore-Tag (W. L. Gore, Flagstaff, Ariz)
specifically granted to our institution and in compliance
with the Institutional Review Board of the Arizona Heart
Hospital.
The Gore Excluder/Gore-Tag is a self-expandable en-
dograft composed of an expanded polytetrafluoroethylene
(ePTFE) tube and external nitinol support system designed
for the thoracic aorta. It is mounted in a flexible delivery
system. A pull string releases the graft, deploying from the
middle of the graft to each end. A trilobular balloon can be
used to further expand the graft post deployment.
Each patient was examined and preoperative studies,
including carotid/vertebral artery duplex and CT of the
chest with and without IV contrast, were reviewed
(Table I). It is then determined if more proximal coverage
is necessary to prevent type I endoleak. If there is a domi-
nant left vertebral artery, patent internal mammary artery,
or concern for postoperative paraplegia (ie, extensive aortic
coverage), left subclavian artery (SCA) revascularization
was performed. Measurements were taken from the CT-
scan and perioperative intravascular ultrasound (IVUS),
and an appropriate endoluminal graft was selected based
upon these measurements and anatomic features. All de-
vices were oversized by at least 2 mm in reference to the
neck diameter.
All procedures were performed in the endovascular/
surgical suite under general anesthesia. Open exposure of
the common femoral artery with the least calcific external
and common iliac arteries was done, meanwhile percutane-
ous access at the contralateral groin and placement of a 5F
sheath was completed. Those with severely diseased iliac
arteries received an iliofemoral conduit through a retroper-
itoneal approach with deployment of the graft via that
conduit (10 mm Dacron tube-graft). Percutaneous bra-
chial access was obtained as necessary depending upon
Table I. Comorbidities and risk factors
HTN 282 (87.0%) ESRD 4 (1.2%)
CAD 116 (35.8%) Obesity 17 (5.2%)
PVOD 123 (38.0%) Hemoptysis 3 (0.9%)
DM 34 (10.5%) AAA repair, prior 20 (6.2%)
COPD 142 (43.8%) Tobacco use 197 (60.8%)
CVD 32 (9.9%) Assoc. trauma 24 (7.4%)
Renal insuff 54 (16.7%)
HTN, Hypertension; CAD, coronary artery disease; PVOD, peripherovas-
cular disease;DM, diabetes mellitus; COPD, chronic obstructive pulmonary
disease;CVD, cerebrovascular disease; ESRD, end stage renal disease;AAA,
abdominal aortic aneurysm.involvement of the aortic arch.Transesophageal echocardiography (TEE) was imple-
mented in complicated dissections or pathologies involving
the more proximal arch. The selected device was advanced
via a Gore sheath (W. L. Gore, Flagstaff, Ariz), a Keller-
Tillerman introducer sheath (Cook, Inc, Bloomington,
Ind), or bare-back with the delivery system alone depen-
dent upon the anatomic constraints of each case.
Statistical analysis was performed utilizing the SPSS
Windows 11.0 program. Logistic regression (univariate)
analysis used to identify risk factors for paraplegia; analysis
of variance (ANOVA) for endoleak distribution; and 2
used to analyze variables. Survival analysis (Log rank test)
was done using SAS version 9.1 (SAS Institute Cary, NC).
A P value  .05 was considered statistically significant.
RESULTS
BetweenMarch 1998 andMarch 2006, 406 patients at
Arizona Heart Hospital were treated for a thoracic pathol-
ogy using endoluminal grafting and 324 were treated with
a Gore endoluminal graft. Of the patients, 200 were male
(61.7%) with a mean age of 72-years-old (range 16 to 91).
The majority of patients were treated for aneurismal disease
(48.5%) and dissections (25.3%) (Table II). Of 324 pa-
tients, 204 (65.1%) required a single graft to correct the
pathology, but three or more grafts (24, 7.4%) were placed
in others (Table III). More than 40 centimeters of the
descending thoracic aorta was covered in 33 patients (10%).
Preoperative aneurysm sac in TAA ranged from 5 to 12 cm,
average size 6.3 cm. Sac shrinkage occurred in 65% of
patients (102/157). Average postoperative sac size of
5.4 cm with a mean follow-up of 20.4 months (3 to 60
months).
Additional procedures were necessary at the time of
deployment. Thirty-seven (10.9%) patients (28 females)
required an iliofemoral conduit via a retroperitoneal ap-
proach to facilitate access and introduce the device. Thirty-
seven (10.9%) patients had the left SCA covered or coiled in
order to gain length proximally for anchoring. Thirteen
(4%) underwent a carotid-subclavian bypass. When the
decision was made for left SCA revascularization, the prox-
imal SCAwas ligated.However, if the SCAwas covered and
a type II endoleak persists, coil embolization was done.
Eight (2.5%) patients underwent thoracic debranching,
and the same number underwent abdominal debranching.
Seven (2.2%) patients underwent perioperative repair of
their abdominal aortic aneurysm with endoluminal grafting
(Table IV). The mean operating room time was 1.75 hours
(range 0.75 to 6.25). The median estimated blood loss of
200cc, range 50 to 3500cc. Median length of stay was 4
days (range 1 to 40 days).
One hundred cases (31.5%) were nonelective, 49
(15.1%) were ruptured. A nonelective case was defined as a
rupture or contained rupture of an aneurysm, pseudoaneu-
rysm, or penetrating ulcer. In addition, any patient whowas
hemodynamically unstable with evidence of hypovolemic
shock, intractable pain, or malperfusion of viscera or limbs
was considered emergent.
ing ul
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plications included respiratory failure (defined as intubated
 72 hours) 19 (5.9%), limb ischemia 9 (2.8%), renal
failure (hemodialysis) 7 (2.2%), cerebrovascular accident 7
(2.2%), bowel ischemia 5 (1.5%), and 4 (1.2%) myocardial
infarctions. Migration occurred in one (0.3%) patient fol-
lowing treatment of an Ao-EF. During the intervention,
thoracic aortic rupture occurred in four (1.2%) patients,
two (0.6%) underwent open conversion. AAA rupture oc-
curred in three (0.9%) patients, two during thoracic inter-
vention, and iliac rupture in five (1.5%) (Table V). Paraple-
gia occurred in five (1.5%) patients and paresis in three
(0.9%), two of the latter improved and one resolved com-
pletely prior to discharge. Incidence of paraplegia was
statistically significant (P value  .05) with retroperitoneal
approach, perioperative blood loss greater than 1000 cc,
and aortic coverage greater than 40 cm. Other variables
evaluated included age (0.291), gender (0.167), pathology
(TAA-0.458, DTB-0.899), rupture (0.999), left SCA cov-
erage (0.118), and previous abdominal aortic coverage
(0.999).
Of those with paraplegia, four of the five received spinal
drains. Sensation improved in one of the four patients, but
function did not return to any. Three of the five patients
died, one at 2 days secondary to suspected pulmonary
embolism, one at 5 days due to intracerebral bleeding
(ICB) with herniation, and one within 30 days due to
multisystem organ failure. Of the three patients with pare-
Table II. Aortic pathologies, age, gender, and nonelective
N (%) Age mean/range
TAA 157 (48.5) 70.5 (35-93)
DTB 82 (25.3) 65.3 (43-88)
PU 34 (10.5) 74.9 (52-91)
PSA 26 (8.0) 63.5 (27-84)
MVAT 11 (3.4) 47.2 (16-74)
AoBF 9 (2.8) 76.5 (52-77)
Emboli 4 (1.2) 76.7 (30-75)
AoEF 1 (0.3) 54
Total 324 (100) 72
TAA, Thoracic aortic aneurysm; DTB, dissection type B; PU, penetrat
AoBF, aorto-bronchial fistula; Emboli, embolization; AoEF, aortoesophagea
Table III. Total number of grafts per pathology
Total endografts
Total1 2 3 4
Aneurysm 89 52 14 2 157
Pseudoaneurysm 24 1 1 0 26
Penetrating ulcer 31 3 0 0 34
Dissection 46 29 6 1 82
Transection 10 0 1 0 11
Embolization 4 0 0 0 4
Aortobrochial fistula 5 4 0 0 9
Aortoenteric fistula 0 1 0 0 1
Total 209 90 22 3 324sis, the one with paraparesis received a spinal drain: symp-toms completely resolved in one leg and improved signifi-
cantly in the other. The other two had monoparesis, one
resolved completely and the other improved significantly
with induced hypertension alone.
Of those seven patients who suffered a CVA, four of the
patients had been treated for dissection (two emergent)
and the remaining three treated for aneurismal disease (one
emergent). Two patients had previous stroke. Five of the
seven improved the symptoms during the postoperative
period. One patient had CVA secondary to major ICB
(Table V).
Early endoleaks included 18 (5.5%) type I, four (1.2%)
type II, and two (0.6%) type III. Incidence of endoleak in
elective interventions was 5.6% and that in nonelective
procedures was 6.0%, (no statistical significance, P  .05)
(Table VI). Twelve of 18 (65%) of the type 1 endoleaks
occurred with thoracic aortic aneurysms. No intervention
in 15 (six of them type I) of 24 endoleaks (62.5%). Of the
six untreated type 1 endoleaks, each with small, distal
endoleak, four resolved without intervention and two re-
main unchanged (one patient with chronic renal failure).
Of those 15 untreated endoleaks, five (three type 1) died
within the immediate postoperative period to causes not
associated with the endoleak. Of the remaining nine type 1
endoleaks, eight received additional ELG and one balloon
angioplasty alone; of these, one had a large persistent
proximal type 1 endoleak treated with open conversion.
Re-intervention related to management of early endoleaks
involved deployment of an additional endoluminal graft in
11 patients, stenting in three patients, and coil emboliza-
tion in one patient (Fig 1).
Late complications included eight (2.5%) type I en-
doleaks, three (0.9%) type II endoleaks, and two type III
endoleaks. Management of late endoleaks included coil
embolization of intercostal branches in two patients, addi-
tional ELG in six cases, and aortic arch debranching in one
patient (Table VII).
Thirty-day mortality was 5.5% (18 related deaths, in-
cluding three intraoperative deaths). A log rank test did not
find statistical differences in actuarial survival with 30-day
related mortality between TAA (P .29) or between DTB
(P .97) and other pathologies (Figs 2 and 3). Late mor-
us
ale (%) Female (%) Nonelective status (%)
87 (55) 70 (45) 24 (15.2)
62 (76) 20 (24) 31 (37.8)
18 (53) 16 (47) 20 (58.8)
16 (62) 10 (38) 8 (30.7)
9 (82) 2 (18) 10 (90)
6 (66) 3 (34) 6 (66.6)
1 (25) 3 (75) 0
1 (100) 0 1 (100)
00 (61.7) 124 (38.3) 100 (31.5)
cer; PSA, pseudoaneurysm; MVAT, motor-vehicle accident transaction;
la.stat
M
2tality was 9.6% with 31 unrelated deaths. Unrelated late
; retro
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show statistical difference when compared to other pathol-
ogies (Figs 4 and 5). Mortality rate with elective procedures
was 4.9% (11 in 224) and 7% (7 in 100) for nonelective
procedures. Follow-up ranged between 1 and 70 months,
average of 17 months.
DISCUSSION
During this past decade, there has been increasing
interest in the use of endoluminal stent grafts as an alterna-
tive treatment for various thoracic aortic pathologies. En-
doluminal therapy has been documented to have less mor-
bidity and mortality when compared with conventional
open thoracic aortic repair. Morbidity and mortality of
open repair has been estimated as high as 20%, with most
estimating the risk of paraplegia at 4%.6 Several studies have
reviewed thoracic endoluminal grafting for acute and elec-
tive cases.8-18,21,27-29 Most of these series consists of a small
number of patients, with as many as 125 patients and mean
Table IV. Adjunctive procedures
Total
Carotid-subcl
bypass
Subcl
embolization
Subcl
ligation/cover emb
Aneurysm 7 2 18
Pseudoaneur 1 0 2
Pene ulcer 0 0 0
Dissection 4 1 11
Transection 0 0 0
Embolization 0 0 0
Aortobrochial
fistula
1 0 3
Aortoenteric
fistula
0 0 0
Total 13 3 34
Subcl, Subclavian; AAA, abdominal aortic aneurysm; elg, endoluminal graft
Table V. Overall complications
Total Elective Nonelective
N/% N/% N/%
Resp failure 19/5.9% 8/3.5% 11/11.0%
Limb ischemia 9/2.8% 7/3.1% 2/2%
Renal failure 7/2.2% 4/1.7% 3/3%
CVA 7/2.2% 4/1.7% 3/3%
Bowel ischemia 5/1.5% 3/1.3% 2/2%
Myocardial infarction 4/1.2% 3/1.3% 1/1%
Graft migration 1/0.3% 0 1/1%
TA rupture 4/1.2% 2/0.8% 2/2%
AAA rupture 3/0.9% 3/1.3% 0
Iliac rupture 5/1.5% 4/1.7% 1/1%
Paraplegia 5/1.5% 4/1.7% 1/1%
Paresis 3/0.9% 2/0.8% 1/1%
Open conversion 2/0.6% 2/0.8% 0
Total 74/22.7% 46 28
HD, Hemodialysis; CVA, cerebrovascular accident; TA, thoracic aorta;
AAA, abdominal aortic aneurysm.follow-up between 11 and 35 months. Although theseseries were small, the results were encouraging. Mortality
ranged from 0% to 10%, total morbidity was as high as
30%, with the incidence of paraplegia between 0% and
12.5%, mean 3.4%. The occurrence of endoleak was be-
tween 0% and 25%, with a mean of 10.6%.
In our series, we reviewed 324 patients who under-
went endografting of the thoracic aorta utilizing the
Gore-Excluder and Gore-Tag device. Overall morbidity
was 22.7% with 2.4% spinal cord ischemia (paraplegia and
paresis). One of the most dramatic observations is the
reduced incidence of paraplegia and paresis. We found the
incidence of paraplegia to be 1.5% and paresis 0.9%, which
is considerably less than that associated with open thoracic
repair.
The occurrence of paraplegia and/or paresis was statis-
tically significant with retroperitoneal approach, the exten-
sion of aortic coverage, and blood loss greater than 1 liter.
With our review of the initial 201 patients, female gender
had a tendency toward increased risk of paraplegia possibly
because they were more likely to receive a retroperitoneal
approach and have a significant portion of the descending
aorta covered. There was no correlation between female
gender and incidence of paraplegia with our most recent
review. We do not fully understand the exact link between
the occurrence of paraplegia and retroperitoneal approach.
We can theorize that the approach predisposes patients to
increased risk of paraplegia because collaterals may be sac-
rificed if ligation of the hypogastric artery occurs. The
increased coverage of the descending thoracic aorta,
needed tomanage a particular pathology, also increased the
incidence of paraplegia due to the resultant coverage of the
descending thoracic aorta leading to sacrifice of more in-
tercostals and spinal arteries.
Covering of the left subclavian artery and previous
abdominal aortic surgery did not prove to be associated
with increased incidence of paraplegia or paresis, however,
a larger sample size of these two subgroups is necessary to
accurately evaluate these factors. Baril et al identified an
increased risk of spinal cord ischemia in those patients that
ion
AAA
elg
AAA
repair
Retroper
approach
Thor
debranching
Abd
debranching
2 2 27 4 8 157
1 0 3 2 0 26
0 0 3 0 0 34
4 1 3 2 0 82
0 0 0 0 0 11
0 0 0 0 0 4
0 0 1 0 0 9
0 0 0 0 0 1
7 3 37 8 8 324
per, retroperitoneal; thor, thoracic; abd, abdominal; pene, penetrating.Sac
olizat
0
0
0
2
0
0
0
0
2had previous or concomitant abdominal aortic repair. In
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endovascular thoracic aortic repair with previous or con-
comitant abdominal aortic repair developed spinal cord
ischemia, while only one of 97 patients (1.0%) among the
remaining thoracic endograft population developed spinal
cord ischemia.30
Of the studies reviewed, four of them noted the need to
cover the left SCA, most followed by carotid-subclavian
bypass. Most of these studies did not show a correlation
between spinal cord ischemia and covering or ligation of
the SCA. However, one study did caution that ligation of
the left SCA.31 Despite left SCA revascularization, one
patient with thoracic aortic debranching developed SCI.
Following this study, we have noted two additional
Table VI. Thoracic pathologies, neurocomplications, end
N (%) Early % endoleak Late % en
TAA 157 (48.5) 19 (12.0) 9 (5
DTB 82 (25.3) 4 (4.8) 3 (3
PU 34 (10.5) 1 (2.9) 0
PSA 26 (8.0) 0 1 (3
MVAT 11 (3.4) 0 0
AoBF 9 (2.8) 0 0
Emboli 4 (1.2) 0 0
AoEF 1 (0.3) 0 0
Total 324(100) 24 (7.4) 13 (4
TAA, Thoracic aortic aneurysm; DTB, dissection type B; PU, penetrat
AoBF, aorto-bronchial fistula; Emboli, embolization; AoEF, aortoesophagea
A
Fig 1. Coil embolization of left subclavian artery. A, E
subclavian artery (small arrow) as ultimately demonstrat
subclavian artery (arrow) to correct a type II endoleak.
Table VII. Endoleak occurrencey
Type I Type II Type III
Early endoleak 18 (5.5%) 4 (1.2%) 2 (0.6%)
TAA 16 (67%) 2 (50%) 1 (50%)
Late endoleak 8 (2.5%) 3 (0.9%) 2 (0.6%)
TAA, Thoracic aortic aneurysm; ns, not significant.
*P  .05  significant.observations of patients who developed paraplegia or pare-sis postoperatively after receiving thoracic ELG. First, hy-
pertension helped to improve or resolve the neurologic
deficit. Most probably, increased systemic pressure im-
proved spinal perfusion. It is our practice to maintain the
patient’s systolic blood pressure approximately 20 mm Hg
above baseline, and/or a mean arterial pressure greater
than 90 mm Hg during the initial 48 hours. Second, any
patient who developed paraplegia, and those with paresis
who was not responsive to medically induced hypertension,
had a spinal drain placed. Weigang et al demonstrated that
the use of intraoperative evoked potentials can served as a
guidance to determine which patient may benefit from SC
drainage and adjustment of vitals.32 Since this series, four
patients developed SCI, three paraplegia and one parapa-
incidence, and 30-day mortality
k CVA Paraplegia Paresis Mortality
3 (1.9) 3 (1.9) 2 (1.2) 11 (7.0)
4 (4.8) 1 (1.2) 1 (1.2) 3 (3.6)
0 1 (2.9) 0 1 (2.9)
0 0 0 1 (3.8)
0 0 0 0
0 0 0 0
0 0 0 1
0 0 0 1
7 (2.1) 5 (1.5) 3 (0.9) 18 (5.5)
cer; PSA, pseudoaneurysm; MVAT, motor-vehicle accident transaction;
la, CVA, cerebrovascular accident.
ak (large white arrow) on CT-scan originated from left
angiography. B, Coil embolization of the origin of the
Total
Endoleak
elective cases
Endoleak
Nonelective cases *P
24 (7.4%) 5.6% 6.0% ns
ns
13 (4.0%) nsoleak
dolea
.7)
.6)
.8)
.0)B
ndole
ed byreis. Spinal drains were placed in each of them. Three of the
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solved one lower extremity deficit and significantly im-
proved in the other. Of these four patients with SCI, three
were female, three had postoperative hypotension, and
none had retroperitoneal approach. Those with more im-
mediate drain placement had the best response. Neurologic
deficits improved or resolved in patients who received
spinal drainage within 6 hours of development of symp-
toms. Since this series, four spinal drains have been placed
prophylactically, two in patients with previous AAA repair
and the others in those with expectant extensive coverage
of the descending thoracic aorta. Prophylactic spinal drains
are placed in those we consider high risk for paraplegia.
This includes those who will require extensive aortic cov-
erage or retroperitoneal approach, particularly those of
female gender. Although it has not been true in our current
series, our initial data showed a correlation between female
gender and increased incidence of SCI. Some members of
our group have placed drains in patients with prior abdom-
inal aortic repair, however, our data has not shown this
Fig 2. Actuarial survival: Related 30-day mortality for TAA vs
other pathologies.
Fig 3. Actuarial survival: Related 30-day mortality for DTB vs
other pathologies.cohort to be at increased risk for paraplegia.Emergent treatment of thoracic aortic pathologies with
endografts proved to be beneficial. Nearly a third of the
cases (31.5%) were nonelective. There was no statistically
significant incidence of complications including paraplegia
and paralysis with these cases (P .170) (Table V); nor was
mortality increased. The occurrence of endoleak also did
not increase with these cases. There were overall 18 (5.5%)
periprocedural type 1 endoleaks and eight (2.5%) late type
1 endoleaks. Urgency of the procedure was not a predictive
factor for increased risk of endoleak (P .186). ANOVA
analysis did prove that the type of pathology, that being
TAA, had increased incidence of all endoleak types, type I,
II, and III (P .049). In reviewing this data, endoluminal
grafting is a feasible alternative to open repair for nonelec-
tive treatment of thoracic aortic injuries and high surgical
risk patients.33-36 This subgroup of patients benefits the
most since open repair in emergent situations carries high
mortality, reported as high as 17% with a paraplegia inci-
dence of 14%.34
Also, the regression of the aneurismal sac is notable.
Fig 4. Actuarial survival: Unrelated 30-day mortality for TAA
vs other pathologies.
Fig 5. Actuarial survival: Unrelated 30-day mortality for DTB
vs other pathologies.Preoperatively, the average sac size was 6.3 cm. Postoper-
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age occurred in 65% (102 of 107) of TAAs. This decrease in
sac size was statistically significant (P  .0001). This find-
ing is encouraging. In our experience, the use of an en-
dograft to treat thoracic aortic pathologies with aneurismal
disease resulted in decreased sac size and in some cases
complete resolution of the sac. Perhaps, changes in thoracic
pressure during the respiratory cycles play an important role
that warrants attention in future studies.
Endografts were used in acute dissections often associ-
ated with malperfusion or intractable pain and in chronic
dissections with aneurismal dilatation. Although contro-
versial, the use of endografts in dissection seems to offer a
new approach for this unique pathology. We believe pa-
tients with this condition can truly benefit from endovas-
cular treatment, often preventing the progression of the
dissection and its associated complications, such as aneuris-
mal dilatation. Prevention of further dilatation and reduc-
tion in the false lumen was evident with endografting. In
our early review of this pathology in 2005, there was a 20%
reduction of aneurismal segments in acute dissection
cases.37 Others agree that the coverage of the entry tear
with the ELG results in decreased diameter of the dissected
aorta with either partial or complete thrombosis of the false
lumen.38 Nienaber et al showed stent-induced aortic re-
modeling for even uncomplicated acute type B aortic dis-
sections.39
Management of symptomatic penetrating aortic ulcers
with ELG is a less invasive and effective treatment. Our
experience in treating this pathology in 34 (10.5%) patients
revealed a 30-day mortality and endoleak incidence of
0%.40 Similar encouraging outcomes have been reported
with other aortic pathologies as such MVAT,24,25,41,42 and
AoBF22 (Fig 6).
CONCLUSIONS
Endoluminal grafting is evolving as a primary treatment
in thoracic pathologies including aneurysms, penetrating
ulcers, pseudoaneurysms, and aortic transections. Patients
with thoracic aneurysms can benefit from endoluminal
grafting, however, anatomy and graft sizing is paramount
in case selection. Limiting the coverage of the descending
aorta may decrease spinal cord ischemia. Although not yet
approved, diverse aortic pathologies can also be safely
treated with ELG with a low incidence of morbidity. Para-
plegia remains significantly low as a complication and in-
creases in incidence with retroperitoneal approach, in-
creased perioperative blood loss, and increased aortic
coverage.
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